News articles about aTyr Pharma (NASDAQ:LIFE) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. aTyr Pharma earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 45.9793201670275 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the headlines that may have impacted Accern Sentiment’s rankings:

aTyr Pharma (LIFE) opened at $3.85 on Monday. The firm has a market cap of $114.57 and a PE ratio of -1.89. aTyr Pharma has a 52 week low of $2.13 and a 52 week high of $6.50. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.49 and a current ratio of 9.49.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.07. research analysts predict that aTyr Pharma will post -1.93 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on LIFE shares. Zacks Investment Research lowered shares of aTyr Pharma from a “buy” rating to a “hold” rating and set a $3.25 price target on the stock. in a research note on Wednesday, August 30th. ValuEngine lowered shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 6th. Finally, Piper Jaffray Companies began coverage on shares of aTyr Pharma in a research note on Thursday, September 7th. They issued an “overweight” rating and a $7.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $4.81.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Insider Buying and Selling by Quarter for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with's FREE daily email newsletter.